YKL-40 genetic polymorphisms and the risk of liver disease progression in patients with advanced fibrosis due to chronic hepatitis C

Liver International

Volumn 32, Issue 4, 2012, Pages 665-674

  Fontana, Robert J ^a   Litman, Heather J ^b   Dienstag, Jules L ^c   Bonkovsky, Herbert L ^d   Su, Grace ^a   Sterling, Richard K ^e   Lok, Anna S ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b NEW ENGLAND RESEARCH INSTITUTES   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^e VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cirrhosis; Decompensation; Genetic polymorphisms; Hepatitis C; Interferon; Virological response

Indexed keywords

FIBROBLAST GROWTH FACTOR; PEGINTERFERON; RIBAVIRIN; UNCLASSIFIED DRUG; YKL 40 PROTEIN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HEPATITIS C; HETEROZYGOTE; HISTOPATHOLOGY; HOMOZYGOTE; HUMAN; LIVER DISEASE; LIVER FIBROSIS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PROMOTER REGION; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREATMENT RESPONSE;

ADIPOKINES; ADULT; DISEASE PROGRESSION; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LECTINS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; RECOMBINANT PROTEINS; RIBAVIRIN;

EID: 84858282993     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02686.x     Document Type: Article

References (30)

1. Kamal SM, Turner B, He Q, et al. Progression of fibrosis in hepatitis C with and without schistosomiasis correlation with serum markers of fibrosis. Hepatology 2006; 43: 771-9.
2. Hu B, Trinh K, Figueira WF, Price PA. Isolation and sequence of novel human chondrocyte protein related to mammalian members of the chitinase protein family. J Biol Chem 1996; 271: 19415-20.
3. Rehli M, Niller HH, Ammon C, et al. Transcriptional regulation of CHI3LI, a marker gene for late stages of macrophage differentiation. J Biol Chem 2003; 278: 44058-67.
4. Baeten D, Boots AM, Steenbakkers PG, et al. Human cartilage gp-39 + CD16 + monocytes in peripheral blood and synovium: correlation with joint destruction in rheumatoid arthritis. Arthritis Rheum 2000; 43: 1233-43.
5. Sztrolovics R, Recklies AD, Roughley PJ, Mort JS. Hyaluronate degradation as an alternative mechanism for proteoglycan release from cartilage during interleukin-1beta stimulated catabolism. Biochm J 2002; 362: 473-9.
6. Malinda KM, Ponce L, Kleinman HK, Shackleton LM, Millis AJ. Gp38k, a protein synthesized by vascular smooth muscle cells, stimulates directional migration of human umbilical vein endothelial cells. Exp Cell Res 1999; 250: 168-73.
7. Nojgaard C, Johansen JS, Christensen E, et al. Serum levels of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease. J Hepatol 2003; 39: 179-86.
8. Mehta P, Ploutz-Snyder R, Nandi J, et al. Diagnostic accuracy of serum hyaluronic acid, FIBROSpect II, and YKL-40 for discriminating fibrosis stages in chronic hepatitis C. Am J Gastroenterol 2008; 103: 928-36.
9. Rehli M, Krause SW, Andreesen R. Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics 1997; 43: 221-5.
10. Ober C, Tan Z, Sun Y, et al. Effect of variation in CHI3L1 on serum YKL-40 level, risk of asthma, and lung function. N Engl J Med 2008; 358: 1682-91.
11. Berres ML, Papen S, Pauels K, et al. A functional variation in CHI3L1 is associated with severity of liver fibrosis and YKL-40 serum levels in chronic hepatitis C infection. J Hepatology 2009; 50: 370-6.
12. Di Bisceglie AM, Shiffman ML, Everson GT, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008; 359: 2429-41.
13. Shiffman ML, DiBisceglie AM, Lindsay KL, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who failed prior treatment. Gastroenterology 2004; 126: 1015-23.
14. Fontana RJ, Goodman ZD, Dienstag JL, et al. Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology 2008; 47: 789-98.
15. Fontana RJ, Bonkovsky HL, Naishadham D, et al. Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis. Clin Gastroenterol Hepatol 2009; 7: 219-26.
16. Fontana RJ, Dienstag JL, Bonkovsky HL, et al., the HALT-C Trial Group. Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut 2010; 59: 1401-9.
17. Ishak KG. Chronic hepatitis: morphology and nomenclature. Mod Pathol 1994; 7: 690-713.
18. Lok ASF, Everhart JE, Chung RT, et al. Hepatic steatosis in hepatitis C: comparison of diabetic and non-diabetic patients in the Hepatitis C Antiviral Long-term Treatment against Cirrhosis Trial. Clin Gastroenterol Hepatol 2007; 5: 245-54.
19. Huang H, Shiffman ML, Cheung RC, et al. Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C. Gastroenterology 2006; 130: 1679-87.
20. Huang H, Shiffman ML, Friedman S, et al. A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology 2007; 46: 297-306.
21. Asselah T, Bieche I, Paradis V, et al. Genetics, genomics, and proteomics: implications for the diagnosis and the treatment of chronic hepatitis C. Sem Liv Dis 2007; 27: 13-27.
22. Bataller R, North KE, Brenner DA. Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal. Hepatology 2003; 37: 493-503.
23. Zhao X, Tang R, Gaso B, et al. Functional variants in the promoter region of chitinase 3-like 1 (CHI3L1) and susceptibility to schizophrenia. Am J Hum Genet 2007; 80: 12-8.
24. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy. Nat Genet 2009; 41: 1100-4.
25. Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virological response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139: 120-9.
26. O'Brien TR, Everhart JE, Chung RT, et al. An IL28B genotype-based model for personalized prediction of response to pegylated-Interferon alfa and ribavirin in the treatment of chronic hepatitis C (Abstract). Hepatology 2010; 62 (Suppl. 1): A127.
27. Curto TM, Lagier RJ, Lok AS, et al., and the HALT-C Trial Group. Predicting Cirrhosis and clinical outcomes in patients with advanced chronic hepatitis C with a panel of genetic markers (CRS7). Pharmacogenet Genomics 2011; 21: 851-60.
28. O'Brien TR, Everhart JE, Morgan TR, et al., and the HALT-C Trial Group. An IL28-B genotype-based clinical prediction model for treatment of chronic hepatitis C. PLos One 2011; 6: e20904.
29. Trepo E, Potthoff A, Pradat P, et al. Role of cirrhosis risk score for the early prediction of fibrosis progression in hepatitis C patients with minimal liver disease. J Hepatology 2011; 55: 38-44.
30. Marcolongo M, Young B, Dal PF, et al. A seven-gene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C. Hepatology 2009; 50: 1028-44.